Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Reolysin (pelareorep)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Adlai Nortye, Andrus Reo, Oncolytics

Drug class:

Apoptosis stimulant

Related drugs:

No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	atezolizumab + pelareorep Sensitive: B - Late Trials atezolizumab + pelareorep Sensitive : B	atezolizumab + pelareorep Sensitive: B - Late Trials atezolizumab + pelareorep Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	pelareorep Sensitive: C3 – Early Trials pelareorep Sensitive : C3	pelareorep Sensitive: C3 – Early Trials pelareorep Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	paclitaxel + pelareorep Sensitive: C3 – Early Trials paclitaxel + pelareorep Sensitive : C3	paclitaxel + pelareorep Sensitive: C3 – Early Trials paclitaxel + pelareorep Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	pelareorep Sensitive: D – Preclinical pelareorep Sensitive : D	pelareorep Sensitive: D – Preclinical pelareorep Sensitive : D